Clinical pharmacology of vasodilator peptides
- PMID: 2455196
Clinical pharmacology of vasodilator peptides
Abstract
Several neuropeptides cause mild flushing when infused intravenously in humans. However, only calcitonin gene-related peptide (CGRP), vasointestinal peptide, and substance P (SP) cause reproducible falls in blood pressure when infused into normal subjects. Of these, CGRP is of the most interest because it is the most potent and because it is present in vascular nerve endings. This paper summarises the evidence to date suggesting that CGRP release from vascular nerve endings may be of physiological importance in the regulation of blood pressure.
Similar articles
-
Substance P regulates the vasodilator activity of calcitonin gene-related peptide.Nature. 1988 Sep 1;335(6185):73-5. doi: 10.1038/335073a0. Nature. 1988. PMID: 2457810
-
CGRP: a novel neuropeptide from the calcitonin gene is the most potent vasodilator known.J Hypertens Suppl. 1986 Dec;4(5):S102-5. J Hypertens Suppl. 1986. PMID: 3553470 Review.
-
Cardiovascular effects of rat calcitonin gene-related peptide in the conscious rat.J Pharmacol Exp Ther. 1988 Oct;247(1):69-78. J Pharmacol Exp Ther. 1988. PMID: 2459371
-
Calcitonin gene-related peptide and tachykinins in relation to local sensory control of cardiac contractility and coronary vascular tone.Acta Physiol Scand Suppl. 1988;569:1-63. Acta Physiol Scand Suppl. 1988. PMID: 3266056
-
The skin as an organ for the study of the pharmacology of neuropeptides.Skin Pharmacol. 1988;1(2):77-83. doi: 10.1159/000210752. Skin Pharmacol. 1988. PMID: 3078645 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials